GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adial Pharmaceuticals Inc (NAS:ADIL) » Definitions » Debt-to-Equity

ADIL (Adial Pharmaceuticals) Debt-to-Equity : 0.00 (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Adial Pharmaceuticals Debt-to-Equity?

Adial Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.00 Mil. Adial Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.00 Mil. Adial Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $4.07 Mil. Adial Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Adial Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

During the past 10 years, the highest Debt-to-Equity Ratio of Adial Pharmaceuticals was 0.07. The lowest was -2.27. And the median was -0.31.

ADIL's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Adial Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Adial Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adial Pharmaceuticals Debt-to-Equity Chart

Adial Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.07 0.06 - -

Adial Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Adial Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Adial Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adial Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adial Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Adial Pharmaceuticals's Debt-to-Equity falls into.


;
;

Adial Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Adial Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Adial Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adial Pharmaceuticals  (NAS:ADIL) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Adial Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Adial Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Adial Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
4870 Sadler Road, Suite 300, Glen Allen, VA, USA, 23060
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
Executives
Kevin Schuyler director 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Stilley William B. Iii director, 10 percent owner, officer: Chief Executive Officer 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Newman James W. Jr. director 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Cary J Claiborne director 3056 SENECA CHIEF TRAIL, ELLICOTT CITY MD 21042
Bankole A. Johnson director, 10 percent owner 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Jack W Reich director C/O COLLATERAL THERAPEUTICS, 11622 EL CAMINO REAL, SAN DIEGO CA 92130
Tony Goodman director 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
J. Kermit Anderson director 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Joseph Truluck officer: COO and CFO 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Robertson H. Gilliland director 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
En Fidecomiso De Mi Vida 11/23/2010 Trust 10 percent owner 11024 GAITHER FARM ROAD, ELLICOTT CITY MD 21042